NCT03481283 A Causative Role for Amylin in Diabetic Peripheral Neuropathy
| NCT ID | NCT03481283 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zabeen Mahuwala, MD |
| Condition | Type2 Diabetes |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2018-02-05 |
| Primary Completion | 2029-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2018-02-05 with a primary completion date of 2029-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Three pieces of information lead to the basis for this study: 1. Individuals with Type-2 diabetes commonly develop peripheral neuropathy. 2. Increased production of the hormone amylin occurs in individuals who have Type-2 diabetes. 3. Aggregations of amylin was found in the peripheral vasculature of rats that overexpressed human amylin. The purpose of this study is to determine whether a correlation exists between the amount of amylin present in the upper extremities of human subjects with Type-2 diabetes and the extent to which symptoms of peripheral neuropathy are expressed in those subjects. The investigators will be testing this by initially collecting blood and skin biopsy samples from subjects, followed by measuring patient sensation and pain responses to heat, cold, and pressure in the upper extremities.
Eligibility Criteria
Inclusion Criteria: * Subject has been diagnosed with Type-2 Diabetes. * Subject shows mild-to-severe peripheral neuropathy, as determined by Nerve Conduction Velocity (NCV) tests. Exclusion Criteria: * Subject has not been diagnosed with Type-2 Diabetes. * Subject shows average, or above average performance on Nerve Conduction Velocity (NCV) tests.
Contact & Investigator
John T Slevin, M.D., M.B.A.
PRINCIPAL INVESTIGATOR
University of Kentucky Department of Neurology
Frequently Asked Questions
Who can join the NCT03481283 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Type2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03481283 currently recruiting?
Yes, NCT03481283 is actively recruiting participants. Contact the research team at rvasireddy@uky.edu for enrollment information.
Where is the NCT03481283 trial being conducted?
This trial is being conducted at Lexington, United States, Lexington, United States.
Who is sponsoring the NCT03481283 clinical trial?
NCT03481283 is sponsored by Zabeen Mahuwala, MD. The principal investigator is John T Slevin, M.D., M.B.A. at University of Kentucky Department of Neurology. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.